Trials / Completed
CompletedNCT01124019
Single Nucleotide Polymorphism (SNP) Panels and Risk Assessment in Women Undergoing Mammography
SNP Panels and Risk Assessment in Women Undergoing Mammography
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,600 (estimated)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Academic / Other
- Sex
- Female
- Age
- 40 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The primary objective is to compare the predicted lifetime risk values produced by SNP panel assessment to the risk values produced by the prediction models that are most commonly used. A second objective is to examine whether the incorporation of risk assessment panels (standard or SNP based) can improve the positive value of breast biopsies in women with BIRADS 4 mammograms.
Detailed description
Calculating the risk that a woman will develop breast cancer in her lifetime can lead to decreased mortality rates as a result of increased screening and prevention methods when a person is known to be at high risk. Though there are several risk assessment models that are commonly used, it is important to continue to improve the process of calculating risk. Several genetic markers have been noted to potentially indicate risk of developing breast cancer. New tests, called SNP panels, can detect some of these genetic markers. This study aims to use both these SNP panels and the commonly used risk models to calculate risk and examine outcomes in women coming in to do screening mammography. This study will enroll women between the ages of 40-65 who are undergoing screening mammography (n=1000), in addition to women with BIRADS category 4 mammogram readings who are about to undergo biopsy (n=600), all with no personal history of breast or ovarian cancer, ductal carcinoma in situ (DCIS), mantle radiation, or known BRCA 1/2/mutation in self or family members. The participants will only be expected rto provide consent, swabs of the inside of the cheek of her mouth, and baseline questionnaire answers that will allow for a risk assessment to be performed.
Conditions
Timeline
- Start date
- 2010-02-01
- Primary completion
- 2012-10-01
- Completion
- 2012-10-01
- First posted
- 2010-05-14
- Last updated
- 2019-03-07
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01124019. Inclusion in this directory is not an endorsement.